Subcutaneous Versus Transvenous Implantable Cardioverter‐Defibrillators in End‐Stage Renal Disease: A Real‐World Study
Pacing and Clinical Electrophysiology · 2026-11 · 49 (11) · 1873-1878
DOI: 10.1111/pace.70330 ↗At a glance
Vergleichsstudie in Pacing and Clinical Electrophysiology, published online on 2026-06-20. Written by Sabin Lama and 6 co-authors. Institution: Harrington Heart & Vascular Institute, School of Medicine, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland,…. Major MEDLINE topics: Kidney Failure, Chronic, Defibrillators, Implantable, Death, Sudden, Cardiac. Cited 1 times so far (Crossref); 8 references.
Abstract (original language)
Background
Patients with end‐stage renal disease (ESRD) on dialysis face a high risk of sudden cardiac death, but traditional transvenous implantable cardioverter‐defibrillators (TV‐ICD) carry risks of central venous stenosis and infection. Subcutaneous implantable cardioverter‐defibrillators (S‐ICD) provide an extravascular alternative, though comparative outcomes in dialysis patients remain limited.
Methods
This study evaluated ESRD patients on hemodialysis who underwent S‐ICD or TV‐ICD implantation between January 2000 and March 2026 using the TriNetX global health network. A 1:1 propensity score matching (PSM) was utilized across 81 clinical covariates. Kaplan‐Meier survival analysis and Cox proportional hazards regression were used to assess long‐term outcomes, including infectious complications, dialysis access revisions, and mortality.
Results
Following PSM, 456 matched pairs ( N = 912) of ESRD patients on dialysis were identified. There were no significant differences between the S‐ICD and TV‐ICD cohorts regarding the composite outcome of sepsis, bacteremia, or transvenous lead extraction (53.5% vs. 55.1%; p = 0.268). All‐cause mortality (58.7% vs. 60.4%; p = 0.747) and hospitalization rates (87.9% vs. 85.4%; p = 0.874) were also similar between the groups. However, S‐ICD was associated with higher rates of composite open and endovascular dialysis access revision (39.1% vs. 25.8%; p = 0.001), percutaneous dialysis access intervention (p = 0.002), and dialysis access surgery ( p = 0.021).
Conclusion
S‐ICD and TV‐ICD demonstrated similar rates of infectious complications, hospitalization, and all‐cause mortality in ESRD patients. S‐ICD implantation was associated with higher rates of dialysis access revisions and interventions. Device selection should remain individualized, guided by anatomy, access planning, and clinical context.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Harrington Heart & Vascular Institute, School of Medicine, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, Ohio, USA.
- School of Medicine, St. George's University, St. George's True Blue, West Indies, Grenada.
ORCID profiles: Sabin Lama, Yusef Saeed
Cite
APA
Lama, S., Saeed, Y., Shahrori, Z., Alhabdan, N., Mahmud, S., Sharma, S., & Sharma, E. (2026). Subcutaneous Versus Transvenous Implantable Cardioverter‐Defibrillators in End‐Stage Renal Disease: A Real‐World Study. Pacing and Clinical Electrophysiology, 49(11), 1873-1878. https://doi.org/10.1111/pace.70330
Vancouver
Lama S, Saeed Y, Shahrori Z, Alhabdan N, Mahmud S, Sharma S, et al. Subcutaneous Versus Transvenous Implantable Cardioverter‐Defibrillators in End‐Stage Renal Disease: A Real‐World Study. Pacing and Clinical Electrophysiology. 2026;49(11):1873-1878. doi:10.1111/pace.70330
BibTeX
@article{Lama2026,
author = {Lama, Sabin and Saeed, Yusef and Shahrori, Zaid and Alhabdan, Nawaf and Mahmud, Shamin and Sharma, Sheila and Sharma, Esseim},
title = {Subcutaneous Versus Transvenous Implantable Cardioverter‐Defibrillators in End‐Stage Renal Disease: A Real‐World Study},
journal = {Pacing and Clinical Electrophysiology},
year = {2026},
volume = {49},
number = {11},
pages = {1873--1878},
doi = {10.1111/pace.70330}
}
EUVIMED